Clinical characteristics and concordance of anti-MDA5 autoantibodies: A multicentre Australian study
Journal Title
Arthritis Care & Research
Abstract
OBJECTIVES: In Australia, anti-MDA5 antibodies are exclusively tested by line immunoblot assay (LIA). The clinical concordance of a LIA-positive anti-MDA5 result is unclear. We aimed to describe the clinical features and determine the clinical concordance of patients with anti-MDA5 antibodies. METHODS: Electronic records of a multisite cohort (patients with positive anti-MDA5 on LIA from three states in Australia from 01/2017-09/2024) were reviewed for clinical features of dermatomyositis (cutaneous manifestations, proximal weakness, interstitial lung disease [ILD]), laboratory investigations and other myositis autoantibodies, and imaging pertaining to the muscles and lungs. RESULTS: Complete clinical data were available for 108/118 patients with positive anti-MDA5 antibodies. A positive test was determined to be clinically concordant in 21/108 (19.4%) patients; these patients had higher signal intensity than those with clinical discordance (52 vs 19.5, p<0.0001). The median age was 65 years (IQR 48-74), and 67% were female. The cohort was predominantly White (n=14), followed by Southeast Asian (n=3), African (n=3), and Middle Eastern (n=1). All 21 patients with anti-MDA5 dermatomyositis had ILD; 7/9 with rapidly progressive ILD (RP-ILD) were deceased at time of review. Patients with RP-ILD had higher ferritin levels (1226 vs 262 μg/L, p<0.05) and neutrophil-to-lymphocyte ratio (4.1 vs 2.6, p<0.05) than patients without RP-ILD. Pneumomediastinum developed in 7/21 (33%); of these, six had RP-ILD, and four subsequently died. Other manifestations included myositis (n=8), cutaneous features (n=14), polyarthritis (n=6) and myocarditis (n=1). CONCLUSION: Higher anti-MDA5 signal intensity on LIA was associated with greater clinical concordance. Pneumomediastinum is common and associated with high mortality.
Research Division(s)
Inflammation
PubMed ID
42606144
Open Access at Publisher's Site
https://doi.org/10.1002/acr.80144
Terms of Use/Rights Notice
Refer to copyright notice on published article.


Creation Date: 2026-08-28 10:52:02
Last Modified: 2026-08-28 10:56:27
An error has occurred. This application may no longer respond until reloaded. Reload 🗙